Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Athenex, Inc. Clear all
Completed Phase 2 Interventional

A Study of Oraxol in Subjects With Cutaneous Angiosarcoma

NCT03544567
View directory record Official record
Conditions
Angiosarcoma of Skin
Interventions
Oraxol
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
New York, New York • Dallas, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

NCT01397799
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
KX2-391
Drug
Lead sponsor
Kinex Pharmaceuticals Inc.
Industry
Eligibility
60 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Buffalo, New York • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

NCT03285490
View directory record Official record
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment 1%, Placebo
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 4, 2026, 6:52 AM EDT
Not listed Phase 1 Interventional

A Phase I Open-label Study for Subjects With Advanced Malignancies

NCT04136834
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
PT01 (Pegtomarginase)
Biological
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies

NCT01967043
View directory record Official record
Conditions
Solid Tumor
Interventions
Oraxol
Drug
Lead sponsor
Kinex Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Aurora, Colorado • Baltimore, Maryland • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies

NCT02326441
View directory record Official record
Conditions
Advance Malignancies
Interventions
KX2-361
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Buffalo, New York • Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

NCT01074138
View directory record Official record
Conditions
Bone-Metastatic, Castration-Resistant Prostate Cancer
Interventions
KX2-391
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies

NCT02250157
View directory record Official record
Conditions
Solid Tumor
Interventions
Oratecan
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Aurora, Colorado • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

NCT02838628
View directory record Official record
Conditions
Actinic Keratosis
Interventions
50 mg of KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fremont, California • La Mesa, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies

NCT02730481
View directory record Official record
Conditions
Solid Tumor
Interventions
Oraxol
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Buffalo, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 4, 2026, 6:52 AM EDT
Terminated Phase 1 Interventional

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

NCT03588039
View directory record Official record
Conditions
Solid Tumor
Interventions
Oraxol, Pembrolizumab
Drug · Biological
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Jacksonville, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 4, 2026, 6:52 AM EDT
Not listed Phase 1 Interventional

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

NCT05487651
View directory record Official record
Conditions
NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
Interventions
KUR-502
Genetic
Lead sponsor
Athenex, Inc.
Industry
Eligibility
3 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies

NCT03987685
View directory record Official record
Conditions
Solid Tumor
Interventions
Oratopo
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

Evaluation of KX2-391 in Patients With Advanced Malignancies

NCT00658970
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
KX2-391
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 4, 2026, 6:52 AM EDT
Not listed Phase 1 Interventional

A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies

NCT02963168
View directory record Official record
Conditions
Solid Tumor
Interventions
Oradoxel
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Rochester, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

NCT03575780
View directory record Official record
Conditions
Actinic Keratoses
Interventions
KX2-391 Ointment 1%
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 4, 2026, 6:52 AM EDT
Not listed Phase 1 Interventional

Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers

NCT02970539
View directory record Official record
Conditions
Gastric Cancer, Esophageal Cancer, Gastro-esophageal Cancer
Interventions
Oraxol, Ramucirumab
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 4, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

NCT02337205
View directory record Official record
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 4, 2026, 6:52 AM EDT